An approach to managing ocular herpes developed by professor A.A. Kasparov, academician of the Russian Academy of Natural Sciences, and his colleagues back in 1970:
Professor Stephen Kaufman, a well-known American ophthalmologist specializing in corneal disorders, referred to the technique as “Russian approach to treating herpes.”
Professor A.A. Kasparov started working on treatment for ocular herpes in the late 1960s. At the time, the only available treatment modalities were corneal scraping with iodine staining, low-efficacy highly toxic chemotherapy drugs (such as Oxolin and Tebrophen), as well as Idoxuridine (IDU), an American drug which became commercially available in 1962. All these medications had limited effect on ocular herpes, were only manufactured in topical forms and caused severe toxic and allergic reactions which placed constraints on their further use.
Once it became clear that available treatment modalities were ineffective, toxic and caused serious complications, a team headed by professor A.A. Kasparov conducted pioneering research into various endogenous interferon inducers and their effects on adenovirus infection of the eye and later herpes. The results were published in 1972 in the form of an article on interferon inducers for ocular herpes.
Soon after, in 1974, professor A.A. Kasparov defended his dissertation dedicated to clinical aspects, diagnosis, etiological and pathogenic treatment of ocular herpes which defined the key principles of the novel approach to ocular herpes treatment based on experimental and clinical data.
Since then, many techniques have been improved, new methods have appeared such as cell technologies (e.g., LEACKT), microdiathermoplasty and amniotic membrane transplantation, and new devices have been developed (new microdiathermy coagulator and excimer laser). That said, the key principles of the method still remain unchanged.
In contrast to the existing Western approach (inhibition of the virus with chemotherapy drugs), professor A.A. Kasparov introduced a polar opposite – immunotherapy, which aimed at strengthening the immune system by inducing production of the patient’s own highly effective interferon.
Poludan is the first interferon inducer which is highly active and remains the best even to this day. Effective treatment strategies employing combinations of Poludan and Acyclovir and other agents have also been developed.
|Treatment methods||Classification||Drug / surgery||Use|
|I Antiviral||Nonspecific immunotherapy||Poludan, endogenous interferon inducer||
|II Surgery||Active surgical treatment at any stage of ocular herpes, including acute stages||
||The choice of modality or combination depends on the depth and extent of corneal damage|
|III Cell technologies||Local express auto-cytokine therapy (LEACKT)||
|IV Antiherpetic vaccine||Specific immunotherapy||Antiherpetic vaccine inactivated by drying||Vaccination every 6 months over the period of 3 years|